Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Account Payables: 2017-2025

Historic Change in Account Payables for Dianthus Therapeutics (DNTH) over the last 6 years, with Sep 2025 value amounting to $3.0 million.

  • Dianthus Therapeutics' Change in Account Payables fell 46.84% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 8.53%. This contributed to the annual value of $8.2 million for FY2024, which is 1139.18% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Change in Account Payables stood at $3.0 million, which was down 2.75% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Change in Account Payables registered a high of $5.7 million during Q3 2024, and its lowest value of -$4.7 million during Q1 2023.
  • In the last 3 years, Dianthus Therapeutics' Change in Account Payables had a median value of $2.3 million in 2024 and averaged $1.2 million.
  • As far as peak fluctuations go, Dianthus Therapeutics' Change in Account Payables crashed by 438.27% in 2023, and later skyrocketed by 631.05% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Change in Account Payables (Quarterly) stood at -$339,000 in 2022, then soared by 572.86% to $1.6 million in 2023, then skyrocketed by 42.23% to $2.3 million in 2024, then plummeted by 46.84% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $3.1 million for Q2 2025, and -$1.5 million during Q1 2025.